Integrated Filing — IndAS



General information about company

Scrip Code 500124
NSE Symbol DRREDDY
MSEI Symbol NOTLISTED
ISIN INE089A01031
Name of company Dr. Reddy's Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 24-10-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 22-09-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Multi segment
Description of single segment
Start date and time of board meeting 24-10-2025   14:00:00
End date and time of board meeting 24-10-2025   15:57:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 23-01-2025
Indicate Company website link for updated RPT policy of the Company https://drreddys.com/cms/sites/default/files/media-library//Policy%20on%20Materiality%20of%20Related%20Party%20Transactions%20and%20Dealing%20with%20Related%20Party%20Transactions%20%281%29.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 4,61,860.00 12,42,810.00
Other income 36,420.00 76,250.00
Total income 4,98,280.00 13,19,060.00
2 Expenses
(a) Cost of materials consumed 1,00,900.00 2,14,450.00
(b) Purchases of stock-in-trade 72,380.00 1,38,760.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (230.00) (21,520.00)
(d) Employee benefit expense 86,790.00 1,75,520.00
(e) Finance costs 3,340.00 5,260.00
(f) Depreciation, depletion and amortisation expense 29,480.00 57,460.00
(f) Other Expenses
1 Impairment of non current assets 370.00 370.00
2 Other Expenses 1,53,620.00 3,03,500.00
Total other expenses 1,53,990.00 3,03,870.00
Total expenses 4,46,650.00 8,73,800.00
3 Total profit before exceptional items and tax 51,630.00 4,45,260.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 51,630.00 4,45,260.00
6 Tax expense
7 Current tax 7,770.00 1,01,940.00
8 Deferred tax 5,130.00 8,470.00
9 Total tax expenses 12,900.00 1,10,410.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 38,730.00 3,34,850.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 38,730.00 3,34,850.00
17 Other comprehensive income net of taxes (8,870.00) (7,020.00)
18 Total Comprehensive Income for the period 29,860.00 3,27,830.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 8,350.00 8,350.00
Face value of equity share capital 1 1
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 4.65 40.23
Diluted earnings (loss) per share from continuing operations 4.65 40.19
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 4.65 40.23
Diluted earnings (loss) per share from continuing and discontinued operations 4.65 40.19
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) Notes are as per results filed with stock exchanges.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 7,00,820.00
Capital work-in-progress 1,70,610.00
Investment property 0.00
Goodwill 8,530.00
Other intangible assets 2,67,690.00
Intangible assets under development 4,300.00
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 11,14,630.00
Trade receivables, non-current 0.00
Loans, non-current 140.00
Other non-current financial assets 26,520.00
Total non-current financial assets 11,41,290.00
Deferred tax assets (net) 19,470.00
Other non-current assets 7,260.00
Total non-current assets 23,19,970.00
2 Current assets
Inventories 4,86,160.00
Current financial asset
Current investments 3,26,960.00
Trade receivables, current 6,63,520.00
Cash and cash equivalents 14,910.00
Bank balance other than cash and cash equivalents 89,230.00
Loans, current 0.00
Other current financial assets 1,25,000.00
Total current financial assets 12,19,620.00
Current tax assets (net)
Other current assets 2,33,310.00
Total current assets 19,39,090.00
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 42,59,060.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 8,350.00
Other equity 31,42,910.00
Total equity attributable to owners of parent 31,51,260.00
Non controlling interest
Total equity 31,51,260.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 25,840.00
Total non-current financial liabilities 25,840.00
Provisions, non-current 1,230.00
Deferred tax liabilities (net) 57,650.00
Deferred government grants, Non-current 0.00
Other non-current liabilities 14,400.00
Total non-current liabilities 99,120.00
Current liabilities
Current financial liabilities
Borrowings, current 3,66,260.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 3,320.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 2,50,060.00
Total Trade payable 2,53,380.00
Other current financial liabilities 2,42,120.00
Total current financial liabilities 8,61,760.00
Other current liabilities 68,770.00
Provisions, current 28,240.00
Current tax liabilities (Net) 49,910.00
Deferred government grants, Current 0.00
Total current liabilities 10,08,680.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 11,07,800.00
Total equity and liabilites 42,59,060.00
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block

Textual Information(1) Notes are as per results filed with stock exchanges.



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1 Pharmaceutical Services and Active Ingredients 80,400.00 1,51,430.00
2 Global Generics 4,01,700.00 11,24,110.00
3 Proprietary Products 0.002 2,770.00
Total Segment Revenue 4,82,300.00 12,78,310.00
Less: Inter segment revenue 20,440.00 35,500.00
Revenue from operations 4,61,860.00 12,42,810.00
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1 Pharmaceutical Services and Active Ingredients 650.00 (1,560.00)
2 Global Generics 59,760.00 4,43,630.00
3 Proprietary Products 480.00 2,740.00
Total Profit before tax 60,890.00 4,44,810.00
i. Finance cost 3,340.00 5,260.00
ii. Other Unallocable Expenditure net off Unallocable income 5,920.00 (5,710.00)
Profit before tax 51,630.00 4,45,260.00
3 (Segment Asset - Segment Liabilities)
Segment Asset
1 Pharmaceutical Services and Active Ingredients 0.00 0.00
2 Global Generics 0.00 0.00
3 Proprietary Products 0.00 0.00
Total Segment Asset 0.00 0.00
Un-allocable Assets 0.00 0.00
Net Segment Asset 0.00 0.00
4 Segment Liabilities
Segment Liabilities
1 Pharmaceutical Services and Active Ingredients 0.00 0.00
2 Global Generics 0.00 0.00
3 Proprietary Products 0.00 0.00
Total Segment Liabilities 0.00 0.00
Un-allocable Liabilities 0.00 0.00
Net Segment Liabilities 0.00 0.00
Disclosure of notes on segments Textual Information(2)



Text Block

Textual Information(2) Notes are as per results filed with stock exchanges.



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
1 Items that will be reclassified to profit or loss (11,860.00) (9,380.00)
Total Amount of items that will be reclassified to profit and loss (11,860.00) (9,380.00)
4 Income tax relating to items that will be reclassified to profit or loss (2,990.00) (2,360.00)
5 Total Other comprehensive income (8,870.00) (7,020.00)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 4,45,260.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 5,260.00
Adjustments for decrease (increase) in inventories (52,770.00)
Adjustments for decrease (increase) in trade receivables, current (68,900.00)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (38,570.00)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current 0.00
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 54,070.00
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 57,830.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 370.00
Adjustments for provisions, current 24,190.00
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 0.00
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains (15,930.00)
Adjustments for dividend income 0.00
Adjustments for interest income 39,050.00
Adjustments for share-based payments 1,970.00
Adjustments for fair value losses (gains) (10,970.00)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 150.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 1,060.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (81,290.00)
Net cash flows from (used in) operations 3,63,970.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 59,810.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 3,04,160.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 57,050.00
Other cash receipts from sales of equity or debt instruments of other entities 8,37,970.00
Other cash payments to acquire equity or debt instruments of other entities 9,26,490.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 860.00
Purchase of property, plant and equipment 99,360.00
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 51,410.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 24,380.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) investing activities (2,71,100.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 2,880.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 27,180.00
Repayments of borrowings 0.00
Payments of lease liabilities 2,190.00
Dividends paid 66,590.00
Interest paid 10,350.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (49,070.00)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (16,010.00)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents (1,050.00)
Net increase (decrease) in cash and cash equivalents (17,060.00)
Cash and cash equivalents cash flow statement at beginning of period 31,970.00
Cash and cash equivalents cash flow statement at end of period 14,910.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 1,800.00 Approved 818.00 0.00 0.00
2 Dr. Reddy's Laboratories Limited Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 7,500.00 Approved 3,517.00 0.00 0.00
3 Dr. Reddy's Laboratories Limited Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Purchase of goods or services 5,800.00 Approved 2,610.00 117.20 209.10
4 Dr. Reddy's Laboratories Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 500.00 Approved 303.30 12.90 3.20
5 Dr. Reddy's Laboratories Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 200.00 Approved 25.70 21.90 1.20
6 Dr. Reddy's Laboratories Limited Indus Projects Private Limited Entities with joint control or significant influence over entity Any other transaction Civil works 3,803.00 Approved 1,355.00 366.10 314.50
7 Dr. Reddy's Laboratories Limited K Satish Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 168.00 Approved 84.00 0.00 0.00
8 Dr. Reddy's Laboratories Limited K Samrajyam Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 24.20 Approved 12.10 0.00 0.00
9 Dr. Reddy's Laboratories Limited K Deepti Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 21.00 Approved 10.50 0.00 0.00
10 Dr. Reddy's Laboratories Limited G Anuradha Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 136.50 Approved 68.30 0.00 0.00
11 Dr. Reddy's Laboratories Limited G.V.Sanjana Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 31.50 Approved 15.80 0.00 0.00
12 Dr. Reddy's Laboratories Limited G.Mallika Reddy Promoters Group Any other transaction Lease rentals paid under cancellable operating leases 26.30 Approved 13.20 0.00 0.00
13 Dr. Reddy's Laboratories Limited DRES Energy Private Limited Joint ventures where entity is venturer Purchase of goods or services 1,410.00 Approved 587.00 0.00 0.00
14 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Sale of goods or services 50,000.00 Approved 22,700.00 11,026.60 10,866.50
15 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Sale of goods or services 9,10,000.00 Approved 5,19,800.00 2,11,118.10 2,56,912.90
16 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Sale of goods or services 40,000.00 Approved 25,000.00 22,480.00 27,022.90
17 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Sale of goods or services 15,000.00 Approved 3,000.00 3,090.00 1,358.30
18 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Sale of goods or services 35,000.00 Approved 15,400.00 19,478.00 19,478.00
19 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Sale of goods or services 18,000.00 Approved (1,200.00) 15,293.60 11,350.10
20 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Sale of goods or services 2,10,000.00 Approved 1,12,100.00 80,580.50 56,314.10
21 Dr. Reddy's Laboratories Limited Dr. Reddy’s Srl Holding-Subsidiary Sale of goods or services 14,000.00 Approved 9,000.00 1,830.70 6,426.20
22 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Sale of goods or services 30,000.00 Approved 15,300.00 16,082.80 22,040.50
23 Dr. Reddy's Laboratories Limited betapharmArzneimittel GmbH, Germany Holding-Subsidiary Sale of goods or services 30,000.00 Approved 17,700.00 12,190.00 16,853.80
24 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Holding-Subsidiary Sale of goods or services 10,000.00 Approved 2,000.00 5,560.60 3,901.60
25 Dr. Reddy's Laboratories Limited Reddy Pharma Iberia SAU, Spain Holding-Subsidiary Sale of goods or services 8,000.00 Approved 5,600.00 4,341.00 8,017.90
26 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Malaysia Sdn. Bhd., Malaysia Holding-Subsidiary Sale of goods or services 5,000.00 Approved 2,600.00 2,544.60 2,391.80
27 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Holding-Subsidiary Sale of goods or services 20,000.00 Approved 9,000.00 10,110.00 12,054.70
28 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SAS, Colombia Holding-Subsidiary Sale of goods or services 7,000.00 Approved 3,400.00 8,822.10 9,008.70
29 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Chile SPA., Chile Holding-Subsidiary Sale of goods or services 5,000.00 Approved 2,000.00 3,370.00 3,869.20
30 Dr. Reddy's Laboratories Limited Reddy Pharma SAS, France Holding-Subsidiary Sale of goods or services 4,000.00 Approved 2,300.00 0.00 231.70
31 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Sale of goods or services 20,000.00 Approved 7,500.00 5,345.40 4,842.20
32 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Canada, Inc., Canada Holding-Subsidiary Sale of goods or services 1,20,000.00 Approved 11,000.00 1,364.00 5,860.70
33 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Thailand) Limited, Thailand Holding-Subsidiary Sale of goods or services 3,000.00 Approved 700.00 578.50 1,015.40
34 Dr. Reddy's Laboratories Limited Dr. Reddy’s New Zealand Limited, New Zealand Holding-Subsidiary Sale of goods or services 3,000.00 Approved 100.00 1,774.20 1,774.20
35 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Sale of goods or services 200.00 Approved 0.00 0.00 10.00
36 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Sale of goods or services 4,000.00 Approved 370.00 0.00 0.00
37 Dr. Reddy's Laboratories Limited Dr. Reddy's Laboratories Philippines Inc. Holding-Subsidiary Sale of goods or services 1,000.00 Approved 200.00 0.00 142.50
38 Dr. Reddy's Laboratories Limited Dr.Reddy’s laboratories Jamaica Limited Holding-Subsidiary Sale of goods or services 5,000.00 Approved 2,800.00 0.00 2,458.20
39 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Sale of goods or services 1,941.00 Approved 753.00 0.00 408.10
40 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Pharmaceuticals Joint ventures where entity is venturer Sale of goods or services 1,300.00 Approved 143.00 43.60 156.40
41 Dr. Reddy's Laboratories Limited Kunshan Rotam Reddy Medical Company Joint ventures where entity is venturer Sale of goods or services 4,400.00 Approved 618.00 0.00 0.00
42 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 2,900.00 1,794.80 1,794.80
43 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 1,200.00 592.20 1,489.60
44 Dr. Reddy's Laboratories Limited Dr. Reddy’s Farmaceutica Do Brasil Ltda., Brazil Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 700.00 125.10 125.80
45 Dr. Reddy's Laboratories Limited Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Holding-Subsidiary Purchase of goods or services 15,000.00 Approved 5,800.00 4,012.30 2,177.50
46 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Purchase of goods or services 40,000.00 Approved 15,800.00 21,400.10 31,037.10
47 Dr. Reddy's Laboratories Limited Dr Reddy’s Laboratories LLP, Kazakhstan Holding-Subsidiary Purchase of goods or services 5,000.00 Approved 2,600.00 2,552.00 2,781.70
48 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Ukraine Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 3,600.00 1,185.30 1,360.40
49 Dr. Reddy's Laboratories Limited Aurigene Oncology Limited, India Holding-Subsidiary Purchase of goods or services 15,000.00 Approved 4,100.00 598.80 1,358.00
50 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Japan KK, Japan Holding-Subsidiary Purchase of goods or services 2,000.00 Approved 300.00 49.50 151.70
51 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Taiwan Limited, Taiwan Holding-Subsidiary Purchase of goods or services 400.00 Approved 200.00 232.50 152.10
52 Dr. Reddy's Laboratories Limited Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited, China Holding-Subsidiary Purchase of goods or services 5,000.00 Approved 1,700.00 1,111.80 1,247.10
53 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (EU) Limited, UK Holding-Subsidiary Purchase of goods or services 10,000.00 Approved 3,600.00 2,053.20 51.30
54 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories (UK) Limited, UK Holding-Subsidiary Purchase of goods or services 100.00 Approved 0.00 0.00 0.00
55 Dr. Reddy's Laboratories Limited Svaas Wellness Limited, India Holding-Subsidiary Purchase of goods or services 3,000.00 Approved 1,000.00 257.90 137.10
56 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Purchase of goods or services 15,065.00 Approved 6,996.00 4,911.40 4,790.60
57 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories Inc., USA Holding-Subsidiary Interest received 12,000.00 Approved 4,500.00 2,445.80 2,560.20
58 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Interest received 5.60 Approved 1.40 0.00 0.00
59 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories SA, Switzerland Holding-Subsidiary Interest received 40,000.00 Approved 17,300.00 0.00 0.00
60 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Commission on guarantee 500.00 Approved 100.00 111.80 123.00
61 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Any other transaction Rental income 500.00 Approved 124.00 86.20 94.80
62 Dr. Reddy's Laboratories Limited Aurigene Pharmaceutical Services Limited, India Holding-Subsidiary Any other transaction Rental income 1,000.00 Approved 422.00 0.00 235.00
63 Dr. Reddy's Laboratories Limited Idea2enterprises (India) Private Limited Holding-Subsidiary Any other transaction Rental Expense 140.00 Approved 68.00 24.00 26.40
64 Dr. Reddy's Laboratories Limited DRL Impex Limited Holding-Subsidiary Any other transaction Rental Expense 40.00 Approved 20.00 7.00 7.70
65 Dr. Reddy's Laboratories Limited Cheminor Investments Limited Holding-Subsidiary Any other transaction Rental Expense 20.00 Approved 10.00 3.00 3.30
66 Dr. Reddy's Laboratories Limited Dr. Reddy’s Bio-sciences Limited, India Holding-Subsidiary Any other transaction Rental Expense 90.00 Approved 46.00 8.00 8.80
67 Dr. Reddy's Laboratories Limited Dr. Reddy’s Laboratories LLC, Russia Holding-Subsidiary Any other transaction Pharmacy chain expenses reimbursement 20,000.00 Approved 12,000.00 0.00 (9,637.00)
68 Aurigene Discovery Technologies (Malaysia) SDN BHD Aurigene Oncology Limited, India Subsidiaries Sale of goods or services 500.00 Approved 200.00 129.20 234.00
69 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 4,000.00 Approved 2,300.00 141.80 (1,600.70)
70 betapharmArzneimittel GmbH, Germany Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 16.80 0.00
71 Dr. Reddy`s Research and Development B.V. (formerly Octoplus BV) Dr. Reddy’s Laboratories Romania SRL Subsidiaries Sale of goods or services 200.00 Approved 0.00 0.00 0.00
72 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories (UK) Limited, UK Subsidiaries Sale of goods or services 500.00 Approved 100.00 0.00 0.00
73 Dr. Reddy’s Laboratories (EU) Limited, UK Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 7,500.00 Approved 2,600.00 3,004.80 5,599.00
74 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
75 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Sale of goods or services 10,000.00 Approved 1,800.00 341.90 216.30
76 Dr. Reddy’s Laboratories Japan KK Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 500.00 Approved 0.00 0.00 0.00
77 Dr. Reddy’s Laboratories Romania SRL Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Sale of goods or services 13,000.00 Approved 6,200.00 5,226.20 7,772.70
78 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Sale of goods or services 10,000.00 Approved 700.00 0.00 0.00
79 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 2,50,000.00 Approved 1,04,600.00 1,24,695.50 1,21,461.40
80 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Kazakhstan LLP Subsidiaries Sale of goods or services 500.00 Approved 0.00 1.40 0.00
81 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Russia Subsidiaries Sale of goods or services 5,000.00 Approved 1,100.00 0.00 1,278.40
82 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories LLC, Ukraine Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
83 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Romania SRL Subsidiaries Sale of goods or services 23,000.00 Approved 13,300.00 0.00 2,546.50
84 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s (Thailand) Limited, Thailand Subsidiaries Sale of goods or services 1,000.00 Approved 0.00 0.00 0.00
85 Dr. Reddy’s Laboratories SA, Switzerland betapharmArzneimittel GmbH, Germany Subsidiaries Sale of goods or services 4,000.00 Approved 300.00 0.00 291.90
86 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Proprietary) Limited, South Africa Subsidiaries Sale of goods or services 4,000.00 Approved 500.00 0.00 217.30
87 Dr. Reddy’s Laboratories SAS, Colombia Dr. Reddy's Laboratories Chile SPA., Chile Subsidiaries Sale of goods or services 500.00 Approved 200.00 0.00 28.00
88 Dr. Reddy’s Srl Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 400.00 Approved 200.00 0.00 35.20
89 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories Inc., USA Subsidiaries Sale of goods or services 3,000.00 Approved 700.00 20.00 211.50
90 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Sale of goods or services 6,000.00 Approved 700.00 1.30 268.70
91 Industrias Quimicas Falcon de Mexico, S.A.de C.V, Mexico Aurigene Pharmaceutical Services Limited, India Subsidiaries Sale of goods or services 4,000.00 Approved 0.00 372.90 0.00
92 Reddy Pharma SAS, France betapharmArzneimittel GmbH, Germany Subsidiaries Sale of goods or services 0.00 Approved 0.00 10.80 0.00
93 Reddy Pharma SAS, France Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 200.00 Approved 0.00 0.00 0.00
94 Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Dr. Reddy’s New Zealand Limited, New Zealand Subsidiaries Sale of goods or services 300.00 Approved 0.00 0.00 0.00
95 Reddy Pharma Iberia SAU, Spain betapharmArzneimittel GmbH, Germany Subsidiaries Sale of goods or services 0.00 Approved 0.00 56.10 0.00
96 Aurigene Pharmaceutical Services Limited, India Aurigene Oncology Limited, India Subsidiaries Sale of goods or services 1,000.00 Approved 300.00 100.10 146.50
97 Dr. Reddy’s Laboratories (UK) Limited, UK Reddy Pharma Iberia SA Subsidiaries Sale of goods or services 0.00 Approved 0.00 0.00 0.00
98 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (UK) Limited Subsidiaries Sale of goods or services 25,000.00 Approved 9,700.00 0.00 3,845.90
99 Dr. Reddy’s Farmaceutica Do Brasil Ltda. Dr. Reddy's Laboratories Chile SPA., Chile Subsidiaries Sale of goods or services 4,000.00 Approved 100.00 0.00 51.80
100 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Subsidiaries Sale of goods or services 11,000.00 Approved 2,100.00 0.00 1,636.10
101 Dr. Reddy’s Laboratories SA, Switzerland Dr.Reddy’s Netherlands BV Subsidiaries Sale of goods or services 10,000.00 Approved 700.00 0.00 682.40
102 Reddy Pharma Iberia SAU, Spain Dr. Reddy’s Srl Subsidiaries Sale of goods or services 200.00 Approved 100.00 0.00 0.00
103 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma SAS, France Subsidiaries Sale of goods or services 5,000.00 Approved 0.00 0.00 0.00
104 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SAU, Spain Subsidiaries Sale of goods or services 2,000.00 Approved 0.00 0.00 0.00
105 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories (Australia) Pty. Limited, Australia Subsidiaries Sale of goods or services 15,000.00 Approved 0.00 0.00 0.00
106 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Royalty Income 1,500.00 Approved 557.00 0.00 0.00
107 Aurigene Oncology Limited Aurigene Pharmaceutical Services Limited, India Subsidiaries Any other transaction Rental Income 500.00 Approved 200.00 394.00 434.00
108 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 100.00 Approved 100.00 0.00 5.90
109 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories Canada, Inc., Canada Subsidiaries Any other transaction Other Income 200.00 Approved 100.00 0.00 0.00
110 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories (EU) Limited, UK Subsidiaries Any other transaction Other Income 0.00 Approved 0.00 0.00 0.00
111 Dr. Reddy’s Laboratories Inc., USA Aurigene Pharmaceutical Services Limited, India Subsidiaries Any other transaction Other Income 3,500.00 Approved 400.00 1,730.00 1,128.70
112 Dr. Reddy’s Laboratories Inc., USA Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 3,700.00 Approved 1,300.00 4,580.00 2,946.00
113 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Subsidiaries Any other transaction Other Income 20,000.00 Approved 3,100.00 0.00 646.70
114 Dr. Reddy`s Research and Development B.V. Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Any other transaction Other Income 0.00 Approved 0.00 0.00 646.70
115 Dr. Reddy’s Laboratories (Canada) Inc. Dr. Reddy’s Laboratories Inc., USA Subsidiaries Any other transaction Other Income 0.00 Approved 0.00 0.00 646.70
116 North Star OpCo Limited Dr. Reddy’s Laboratories (UK) Limited, UK Subsidiaries Any other transaction Other Income 1,500.00 Approved 500.00 0.00 471.80
117 Dr. Reddy’s Laboratories SA, Switzerland North Star OpCo Limited Subsidiaries Any other transaction Other Income 1,500.00 Approved 500.00 0.00 471.80
118 Aurigene Oncology Limited Aurigene Pharmaceutical Services Limited, India Subsidiaries Interest received 0.00 Approved 0.00 0.00 0.00
119 betapharmArzneimittel GmbH, Germany Nimbus Health GmbH Subsidiaries Interest received 50.00 Approved 0.00 0.00 0.00
120 betapharmArzneimittel GmbH, Germany Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 2,200.00 Approved 1,229.00 0.00 0.00
121 Dr. Reddy`s Research and Development B.V. Reddy Netherlands B.V. Subsidiaries Interest received 600.00 Approved 0.00 0.00 0.00
122 Dr. Reddy’s Laboratories (EU) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 200.00 Approved 106.00 0.00 0.00
123 Dr. Reddy’s Laboratories (UK) Limited, UK Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 2,400.00 Approved 850.00 0.00 0.00
124 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy`s Research and Development B.V. Subsidiaries Interest received 140.00 Approved 83.00 0.00 0.00
125 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories (Australia) Pty. Limited Subsidiaries Interest received 100.00 Approved 64.00 0.00 0.00
126 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy's Laboratories Philippines Inc. Subsidiaries Interest received 10.00 Approved 8.00 0.00 0.00
127 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories SAS, Colombia Subsidiaries Interest received 40.00 Approved 19.00 0.00 0.00
128 Dr. Reddy’s Laboratories SA, Switzerland Dr. Reddy’s Laboratories Chile SPA., Chile Subsidiaries Interest received 40.00 Approved 19.00 0.00 0.00
129 Dr. Reddy’s Laboratories SA, Switzerland Reddy Pharma Iberia SA Subsidiaries Interest received 111.00 Approved 53.00 0.00 0.00
130 Lacock Holdings Limited Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 3.00 Approved 2.00 0.00 0.00
131 Dr. Reddy’s Laboratories SA, Switzerland Northstar OpCo Subsidiaries Interest received 24.00 Approved 13.00 0.00 0.00
132 Dr. Reddy’s Srl Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 128.00 Approved 64.00 0.00 0.00
133 Reddy Pharma SAS, France Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 82.00 Approved 41.00 0.00 0.00
134 Dr. Reddy’s Laboratories SA, Switzerland Northstar Switzerland SARL Subsidiaries Interest received 38.00 Approved 19.00 0.00 0.00
135 Reddy Netherlands B.V. Dr. Reddy`s Research and Development B.V. (formerly Octoplus BV) Subsidiaries Interest received 100.00 Approved 49.00 0.00 0.00
136 Northstar Switzerland SARL Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 1,000.00 Approved 721.00 0.00 0.00
137 North Star OpCo Limited Dr. Reddy’s Laboratories SA, Switzerland Subsidiaries Interest received 200.00 Approved 56.00 0.00 0.00
138 Dr. Reddy’s Laboratories SA, Switzerland Dr Reddy's Denmark ApS Subsidiaries Interest received 525.00 Approved 234.00 0.00 0.00
139 Dr. Reddy’s Laboratories SA, Switzerland North Star Sweden AB Subsidiaries Interest received 2.00 Approved 1.00 0.00 0.00
140 Dr. Reddy's Laboratories Limited Naandi Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 42.00 0.00 0.00
141 Dr. Reddy's Laboratories Limited PAGE Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 475.00 Approved 475.00 0.00 0.00
142 Dr. Reddy's Laboratories Limited Wildlife Trust of India Entities with joint control or significant influence over entity Any other transaction Contributions for social development 113.00 Approved 50.00 0.00 0.00
143 Dr. Reddy's Laboratories Limited NICE Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 250.00 Approved 112.00 0.00 0.00
144 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Purchase 1,270.00 Approved 375.00 0.00 34.00
145 Dr. Reddy's Laboratories Limited Zenfold Sustainable Technologies Private Limited Entities with joint control or significant influence over entity Any other transaction Sale 90.00 Approved 38.00 0.00 26.00
146 Dr. Reddy's Laboratories Limited Indian School of Business Entities with joint control or significant influence over entity Any other transaction Campus placement, training and development services 5.00 Approved 2.00 0.00 0.00
147 Dr. Reddy’s Bio-sciences Limited, India DRES Energy Private Limited Joint ventures where entity is venturer Any other transaction Rental income 6.00 Approved 3.00 0.00 0.00
148 Aurigene Pharmaceutical Services Limited, India Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 20.00 Approved 0.00 0.00 0.00
149 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 100.00 Approved 0.00 0.00 0.00
150 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Annual facility maintenance cost Vaccine Development Lab 600.00 Approved 0.00 0.00 0.00
151 Dr. Reddy's Laboratories Limited Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Any other transaction Lab facility - Center of Excellence (CoE) for advanced and novel parenteral formulations 460.00 Approved 20.00 0.00 0.00
152 Aurigene Pharmaceutical Services Limited, India Dr.Reddy’s Institute of Life Sciences Entities with joint control or significant influence over entity Purchase of goods or services 100.00 Approved 0.00 0.00 0.00
153 Aurigene Pharmaceutical Services Limited, India Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 20.00 Approved 10.00 0.00 0.00
154 Aurigene Oncology Limited Stamlo Industries Limited Entities with joint control or significant influence over entity Purchase of goods or services 10.00 Approved 0.00 0.00 0.00
155 Aurigene Pharmaceutical Services Limited, India Green Park Hospitality Services Private Limited Entities with joint control or significant influence over entity Purchase of goods or services 150.00 Approved 70.00 10.00 10.00
156 Aurigene Oncology Limited Greenpark Hotel and Resorts Limited Entities with joint control or significant influence over entity Purchase of goods or services 10.00 Approved 0.00 0.00 0.00
157 Aurigene Oncology Limited Clean Renewable Energy KK 2A Pvt Ltd Entities with joint control or significant influence over entity Purchase of goods or services 720.00 Approved 140.00 0.00 0.00
158 Aurigene Oncology Limited Dr.Reddy’s Foundation Entities with joint control or significant influence over entity Any other transaction Contributions for social development 30.00 Approved 0.00 0.00 0.00
159 Dr. Reddy's Laboratories Limited Dr. Reddy’s Formulations Limited Holding-Subsidiary Loan 70.00 Approved 0.00 70.00 0.00
160 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Manpower services provided by DRL India 8,045.00 Approved 3,768.00 0.00 0.00
161 Dr. Reddy's Laboratories Limited Dr. Reddy's Nestle and Health Science Limited Holding-Subsidiary Any other transaction Marketing and promotional services provided by DRL India 1,811.00 Approved 456.00 0.00 0.00
162 Dr. Reddy's Laboratories Limited G V Prasad Key management personnel of entity or parent Remuneration 2,030.00 Approved 139.40 0.00 0.00
163 Dr. Reddy's Laboratories Limited K Satish Reddy Key management personnel of entity or parent Remuneration 1,260.00 Approved 139.40 0.00 0.00
164 Dr. Reddy's Laboratories Limited Deepak Sapra Key management personnel of entity or parent Remuneration 500.00 Approved 273.10 0.00 0.00
165 Dr. Reddy's Laboratories Limited Mannam Venkata Narasimham Key management personnel of entity or parent Remuneration 560.00 Approved 304.00 0.00 0.00
166 Dr. Reddy's Laboratories Limited M V Ramana Key management personnel of entity or parent Remuneration 900.00 Approved 488.40 0.00 0.00
167 Dr. Reddy's Laboratories Limited Krishna Venkatesh Key management personnel of entity or parent Remuneration 410.00 Approved 220.40 0.00 0.00
168 Dr. Reddy's Laboratories Limited Milan Kalawadia Key management personnel of entity or parent Remuneration 820.00 Approved 453.30 0.00 0.00
169 Dr. Reddy's Laboratories Limited Archana Bhaskar Key management personnel of entity or parent Remuneration 670.00 Approved 363.20 0.00 0.00
170 Dr. Reddy's Laboratories Limited Sanjay Sharma Key management personnel of entity or parent Remuneration 690.00 Approved 372.40 0.00 0.00
171 Dr. Reddy's Laboratories Limited Erez Israeli Key management personnel of entity or parent Remuneration 2,440.00 Approved 1,315.40 0.00 0.00
172 Dr. Reddy's Laboratories Limited Patrick Aghanian Key management personnel of entity or parent Remuneration 1,010.00 Approved 571.00 0.00 0.00
173 Dr. Reddy's Laboratories Limited Sushrut Kulkarni Key management personnel of entity or parent Remuneration 600.00 Approved 326.20 0.00 0.00
174 Dr. Reddy's Laboratories Limited Kumar Randhir Singh Key management personnel of entity or parent Remuneration 100.00 Approved 58.40 0.00 0.00
175 Dr. Reddy's Laboratories Limited Bhethanabottla S Phanimitra Key management personnel of entity or parent Remuneration 360.00 Approved 208.20 0.00 0.00
176 Dr. Reddy's Laboratories Limited Jayanth Sridhar Key management personnel of entity or parent Remuneration 390.00 Approved 304.80 0.00 0.00
177 Dr. Reddy's Laboratories Limited Akhil Ravi Relatives of Key management personnel Remuneration 150.00 Approved 120.50 0.00 0.00
178 Dr. Reddy's Laboratories Limited Vishal Reddy Relatives of Key management personnel Remuneration 50.00 Approved 41.30 0.00 0.00
179 Dr. Reddy's Laboratories Limited Shravya Reddy Kallam Relatives of Key management personnel Remuneration 20.00 Approved 13.30 0.00 0.00
Total value of transaction during the reporting period 10,54,553.00